NASDAQ:TSBX - Nasdaq - US90042W1009 - Common Stock - Currency: USD
0.3629
0 (-0.82%)
The current stock price of TSBX is 0.3629 USD. In the past month the price increased by 8.62%. In the past year, price decreased by -86.56%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 18.45 | 334.73B | ||
AMGN | AMGEN INC | 14.13 | 157.78B | ||
GILD | GILEAD SCIENCES INC | 14.22 | 136.94B | ||
VRTX | VERTEX PHARMACEUTICALS INC | N/A | 115.95B | ||
REGN | REGENERON PHARMACEUTICALS | 11.82 | 56.53B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 39.44B | ||
ARGX | ARGENX SE - ADR | 100.08 | 35.14B | ||
ONC | BEONE MEDICINES LTD-ADR | 6.74 | 28.50B | ||
BNTX | BIONTECH SE-ADR | N/A | 25.70B | ||
NTRA | NATERA INC | N/A | 22.56B | ||
BIIB | BIOGEN INC | 8.56 | 19.85B | ||
INSM | INSMED INC | N/A | 16.56B |
Turnstone Biologics Corp. operates as a clinical stage biotechnology company. The company is headquartered in La Jolla, California and currently employs 14 full-time employees. The company went IPO on 2023-07-21. The firm is focused on developing new medicines to treat and cure patients with solid tumors. The company is developing tumor infiltrating lymphocytes (TIL) therapies for the potential treatment of multiple solid tumors. The company is also actively advancing its preclinical pipeline programs including TIDAL-02, its next Selected TIL program, and its TIDAL-01 and viral immunotherapy combination program. The company is advancing TIDAL-01, its lead Selected TIL product candidate, for the treatment of multiple solid tumor indications. TIDAL-01 utilizes an unbiased identification and functional screening process to isolate and selectively expand the greatest breadth of tumor-reactive TILs from the patient’s tumor. Its next Selected TIL program, TIDAL-02, is being designed to encompass a next generation streamlined manufacturing process for tumor-reactive T cells and additional modifications to enhance TIL quality and function.
TURNSTONE BIOLOGICS CORP
9310 Athena Circle, Suite 300
La Jolla CALIFORNIA US
Employees: 82
Phone: 13478975988
The current stock price of TSBX is 0.3629 USD. The price decreased by -0.82% in the last trading session.
The exchange symbol of TURNSTONE BIOLOGICS CORP is TSBX and it is listed on the Nasdaq exchange.
TSBX stock is listed on the Nasdaq exchange.
6 analysts have analysed TSBX and the average price target is 1.02 USD. This implies a price increase of 181.07% is expected in the next year compared to the current price of 0.3629. Check the TURNSTONE BIOLOGICS CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.
TURNSTONE BIOLOGICS CORP (TSBX) has a market capitalization of 8.40M USD. This makes TSBX a Nano Cap stock.
TURNSTONE BIOLOGICS CORP (TSBX) currently has 82 employees.
TURNSTONE BIOLOGICS CORP (TSBX) has a support level at 0.32 and a resistance level at 0.37. Check the full technical report for a detailed analysis of TSBX support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
TSBX does not pay a dividend.
TURNSTONE BIOLOGICS CORP (TSBX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.73).
The outstanding short interest for TURNSTONE BIOLOGICS CORP (TSBX) is 1.68% of its float. Check the ownership tab for more information on the TSBX short interest.
ChartMill assigns a technical rating of 2 / 10 to TSBX. When comparing the yearly performance of all stocks, TSBX is a bad performer in the overall market: 95.36% of all stocks are doing better.
ChartMill assigns a fundamental rating of 2 / 10 to TSBX. While TSBX seems to be doing ok healthwise, there are quite some concerns on its profitability.
Over the last trailing twelve months TSBX reported a non-GAAP Earnings per Share(EPS) of -2.73. The EPS increased by 73.08% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -228.2% | ||
ROE | -315.29% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 43% to TSBX. The Buy consensus is the average rating of analysts ratings from 6 analysts.